Literature DB >> 24488939

Position statement: National Gaucher Foundation Medical Advisory Board, January 7, 2014.

John A Barranger1, Roscoe O Brady, Gregory A Grabowski, Henry Mankin, Pramod K Mistry, Neal J Weinreb.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 24488939     DOI： 10.1002/ajh.23687

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  3 in total

1.  Healthcare resource utilization and cost of care for Gaucher patients in Iran.

Authors:  Majid Davari; Azita Nabizadeh; Maliheh Kadivar; Akbar Abdollahi Asl; Peymaneh Sarkheil
Journal:  J Diabetes Metab Disord       Date:  2019-04-09

2.  Evaluation of disease burden and response to treatment in adults with type 1 Gaucher disease using a validated disease severity scoring system (DS3).

Authors:  Neal J Weinreb; David N Finegold; Eleanor Feingold; Zhen Zeng; Barry E Rosenbloom; Suma P Shankar; Dominick Amato
Journal:  Orphanet J Rare Dis       Date:  2015-05-22       Impact factor: 4.123

3.  Stability is maintained in adults with Gaucher disease type 1 switched from velaglucerase alfa to eliglustat or imiglucerase: A sub-analysis of the eliglustat ENCORE trial.

Authors:  Rebecca Pleat; Timothy M Cox; T Andrew Burrow; Pilar Giraldo; Ozlem Goker-Alpan; Barry E Rosenbloom; Laura R Croal; Lisa H Underhill; Sebastiaan J M Gaemers; M Judith Peterschmitt
Journal:  Mol Genet Metab Rep       Date:  2016-09-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.